Impaired cerebral vasoreactivity in patients with Parkinson’s disease: clinical and imaging correlates
Objective: To determine the clinical and imaging correlates of impaired cerebral autoregulation as measured with cerebral vasoreactivity (CVR) in patients with idiopathic Parkinson’s disease (PD).…Characteristics of spontaneous brain activity in left- and right-onset Parkinson’s disease patients
Objective: To explore the characteristics of spontaneous brain activity in left- and right-onset Parkinson’s disease (PD) patients Background: It is well-know that PD patients often…Progression of dopaminergic and serotonergic dysfunction related to motor and nonmotor manifestations in apathetic and non-apathetic parkinsonian patients: a 4-year longitudinal double-tracer PET study
Objective: To investigate the progression of dopaminergic and serotonergic dysfunction and their relation to motor and nonmotor impairment in parkinsonian patients with or without apathy,…Non-Invasive Vagus Nerve Stimulation: A non-pharmacological approach to target gait impairment in Parkinson’s disease?
Objective: To determine whether single dose non-invasive vagus nerve stimulation (nVNS) enhances gait performance in Parkinson’s (PD). Background: Loss of cholinergic neurons from nucleus basalis…An explorative study on the value of clinical features for diagnosing Parkinson’s disease
Objective: To investigate the usefulness of clinical features to differentiate subjects with “scans without evidence of dopaminergic deficit” (SWEDD) from patients presumed to have Parkinson’s…Long-term impact of Levodopa Carbidopa Intestinal Gel (LCIG) on reducing “Off” time: Results from a systematic review of studies with ≥ 12 months of follow-up
Objective: The objective of this study was to summarize evidence evaluating long-term (i.e. ≥ 12 months)efficacy of levodopa carbidopa intestinal gel (LCIG) on “off” time,…Changes to Speech Production after SpeechVive Treatment in Individuals with Parkinson’s Disease
Objective: The purpose of the present study was to assess the effects of a device-driven treatment (SpeechVive) on respiratory and laryngeal function after 8 weeks…Continuous circadian intracerebroventricular administration of anaerobic dopamine: A new therapeutic concept for Parkinson’s disease?
Objective: We aim to overcome these challenges by demonstrating that continuous i.c.v. of Anaerobic-dopamine (A-dopamine,Patent #WO2015173258 A1) close to the striatum is a feasible and…Yerba mate tea (Ilex paraguariensis) exerts a neuroprotective effect on intrastriatal 6-OHDA-lesioned mice model of Parkinson’s disease
Objective: We set to investigate the possible neuroprotective effect of yerba mate (YM) consumption on dopaminergic neurons in a mice model of Parkinson’s disease (PD). Background: The motor…Progression of neuropsychiatric symptoms in Parkinson’s disease
Objective: To determine the progression of neuropsychiatric symptoms (NPS) in Parkinson’s disease (PD) and their associations with quality of life (QoL) and motor problems. Background:…
- « Previous Page
- 1
- …
- 154
- 155
- 156
- 157
- 158
- …
- 388
- Next Page »